Professor Feng Yibin is currently the Director of the School of Chinese Medicine, the University of Hong Kong, and a member of the Chinese Pharmacopoeia Committee. Mainly engaged in the research of integrated Chinese and Western Medicine in the prevention and treatment of cancer and metabolic diseases with Chinese Medicine. He has published more than 200 SCI papers. He also serves as editorial board members and reviewers for more than 70 international journals. Since 2017, according to the Essential Science Indicator (ESI), he has been listed as one of the top 1% researchers worldwide for 6 consecutive years, and has also been listed as one of the world’s top 2% scientists by Stanford University.